본문으로 건너뛰기
← 뒤로

The Impact of Race and Socioeconomic Status on Management of Potentially Resectable Pancreatic Cancer: Analysis From a Metropolitan Area in the Southeast United States.

The American surgeon 2026 Vol.92(5) p. 1498-1507 Pancreatic and Hepatic Oncology Rese
TL;DR It is demonstrated that patients with PDAC can receive similar treatment despite differences in race and SES, and Interestingly, Black patients presented at a significantly younger age, warranting further evaluation of risk factors and tumor biology.
OpenAlex 토픽 · Pancreatic and Hepatic Oncology Research Global Cancer Incidence and Screening Advances in Oncology and Radiotherapy

Patel DD, Brashier S, Fleming AM, Glazer ES, Aitken GL, Dickson PV

📝 환자 설명용 한 줄

It is demonstrated that patients with PDAC can receive similar treatment despite differences in race and SES, and Interestingly, Black patients presented at a significantly younger age, warranting fur

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Devanshi D. Patel, Samantha Brashier, et al. (2026). The Impact of Race and Socioeconomic Status on Management of Potentially Resectable Pancreatic Cancer: Analysis From a Metropolitan Area in the Southeast United States.. The American surgeon, 92(5), 1498-1507. https://doi.org/10.1177/00031348251399190
MLA Devanshi D. Patel, et al.. "The Impact of Race and Socioeconomic Status on Management of Potentially Resectable Pancreatic Cancer: Analysis From a Metropolitan Area in the Southeast United States.." The American surgeon, vol. 92, no. 5, 2026, pp. 1498-1507.
PMID 41237301

Abstract

BackgroundSocial determinants of health are associated with differences in care and outcomes for pancreatic ductal adenocarcinoma (PDAC) patients. This study evaluates the impact of race and socioeconomic status (SES) on the presentation, management, and survival of patients with potentially resectable PDAC within a metropolitan hospital system in the Southeast United States.MethodsA retrospective analysis of PDAC patients (2014-2020) across a multi-hospital system was performed. Associations between race as well as socioeconomic and clinicopathologic data with presentation, treatment, and survival were analyzed.ResultsAmong 222 patients, 104 (46.9%) were Black and 118 (53.1%) were White. Black patients presented at a significantly younger age (61 vs 66, = 0.007) and resided within the lowest 2 quintiles for median income (68.2% vs 42.4%, < 0.0001). Compared with White patients, Black patients were more likely to have Medicaid/no insurance (22.1% vs 11.9%, = 0.040). Receipt of multimodal therapy and curative intent resection was not significantly different between Black and White patients (80% vs 84.3%, = 0.372; 46% vs 54.6%, = 0.275), ≤50th percentile vs > 50th percentile income (79.5% vs 85.1%, = 0.358; 47.6% vs 53.8%, = 0.428), or Medicare/private vs Medicaid/no insurance (84.4% vs 71.4% = 0.120; 50% vs 53.8%, = 0.719). On survival analysis, outcomes were determined by receipt of multimodal treatment and histopathological factors but did not differ based on race or SES.DiscussionThis analysis demonstrates that patients with PDAC can receive similar treatment despite differences in race and SES. Interestingly, Black patients presented at a significantly younger age, warranting further evaluation of risk factors and tumor biology.

MeSH Terms

Humans; Pancreatic Neoplasms; Male; Female; Retrospective Studies; Aged; Middle Aged; Social Class; Black or African American; Carcinoma, Pancreatic Ductal; White People; Southeastern United States; Healthcare Disparities; Pancreatectomy; White